Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Melphalan Dose in Myeloma Patients over 65 Years of Age Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Guido Ghilardi, MD, Thomas Pabst, MD, Barbara Jeker, MD, Rouven Müller, MD, Anne Cairoli, MD, Antonia Mueller, MD, Mario Bargetzi, MD, Felicitas Hitz, MD, Helen Baldomero, Dominik Heim, MD, Davide Rossi, MD PhD, Michele Ghielmini, MD, Erika Lerch, MD, Urs Schanz, MD, Jakob R. Passweg, MDMS, Georg Stussi, MD, Martina Kleber, MD, Bernhard Gerber

Blood (2017) 130 (Supplement 1): 3297.

https://doi.org/10.1182/blood.V130.Suppl_1.3297.3297

Published: 2017

Journal Articles

First Results of the Interdisciplinary Comprehensive Cancer Center Freiburg (CCCF) Tumor Board (TB) Multiple Myeloma (MM) Assessing TB-Questions, TB-Advice Adherence, TB-Satisfaction of Patients, Participants and Referring Physicians, Inclusion of Difficult-to-Treat-MM Pts in Clinical Trials (CT) and Patient Outcome

Ricarda Selder, Masa Pandurevic, Mandy-Deborah Möller, Johannes Waldschmidt, MD, Milena Pantic, Georg W. Herget, Karl Henne, Annette May, Martina Kleber, MD, Josefina Udi, MD, Gabriele Ihorst, Rainer Bredenkamp, Werner Vach, Justus Duyster, MD, Ralph Wäsch, MD, Monika Engelhardt, MD

Blood (2014) 124 (21): 2635.

https://doi.org/10.1182/blood.V124.21.2635.2635

Published: 2014

Journal Articles

Importance and Determinants of Comorbidities, Functional Limitations and Multiple Myeloma (MM)-Specific Risk Factors: Further Development of an Improved and Weighted MM-Risk Score (Freiburg Comorbidity Index [FCI])

Anne-Saskia Domm, Stefanie Hieke, Gabriele Ihorst, Milena Pantic, Bernd Koch, Martina Kleber, MD, Johannes Waldschmidt, MD, Martin Schumacher, PhD, Ralph Wäsch, MD, Monika Engelhardt, MD

Blood (2014) 124 (21): 733.

https://doi.org/10.1182/blood.V124.21.733.733

Published: 2014

Journal Articles

R-Mini-CHOP Versus R-Bendamustine As Primary Treatment for Diffuse Large B-Cell Lymphoma (DLBCL) in Elderly and Comorbid Patients

Jakob Hammersen, Maria Madeleine Rüthrich, Martina Kleber, Ulrich Wedding, Michael Sommer, Daniela Müller, Peter Schlattmann, Andreas Hochhaus, MD, Paul La Rosee

Blood (2014) 124 (21): 5436.

https://doi.org/10.1182/blood.V124.21.5436.5436

Published: 2014

Journal Articles

Third Autologous Salvage Transplant at Late Myeloma Relapse Is Associated with Favourable Overall Survival and Contributes to Improvement of Exhausted Bone Marrow Function

Susanne Strifler, MD, Inken Hilgendorf, MD, Martina Kleber, MD, Christoph Röllig, MD, Lars-Olof Mügge, MD, Maria-Veronica Teleanu, MD, Brigitte Kragl, MD, Hermann Einsele, MD, Stefan Knop, MD

Blood (2014) 124 (21): 3988.

https://doi.org/10.1182/blood.V124.21.3988.3988

Published: 2014

Journal Articles

Vorinostat (V) In Combination With Bortezomib (B), Doxorubicin (D) and Dexamethasone (D) (VBDD) In Patients With Refractory Or Relapsed Multiple Myeloma: An Interim Phase I/II Analysis

Martina Kleber, Dagmar Wider, Kristina Keller, Barbara Groß, Heike Reinhardt, Dorothee Jakobs, Mandy-Deborah Moeller, Manuela Burbeck, Milena Pantic, Annette May, Manfred Jung, PhD, Ralph Waesch, MD, Monika Engelhardt, MD

Blood (2013) 122 (21): 3202.

https://doi.org/10.1182/blood.V122.21.3202.3202

Published: 2013

Journal Articles

Estimation Of GFR With Different EGFR Equations In Multiple Myeloma Patients Receiving Lenalidomide Treatment

Martina Kleber, Bernd Koch, Ralph Waesch, MD, Monika Engelhardt, MD

Blood (2013) 122 (21): 5324.

https://doi.org/10.1182/blood.V122.21.5324.5324

Published: 2013

Journal Articles

Second Malignant Neoplasms Following Multiple Myeloma: A Cohort Study On 744 Patients Treated 1997-2011

Martina Kleber, Kerstin Höck, Gabriele Ihorst, Bernd Koch, Ralph Waesch, MD, Ola Landgren, MD, PhD, Monika Engelhardt, MD

Blood (2013) 122 (21): 3100.

https://doi.org/10.1182/blood.V122.21.3100.3100

Published: 2013

Journal Articles

Targeting The Protective Microenvironment In Multiple Myeloma (MM): An Analysis Of The CXCL12/CXCR4-Axis and Its Inhibitors AMD3100 and Nox-A12 Combined With Antimyeloma Substances, Such As Pomalidomide and Carfilzomib

Anna Simon, Dagmar Wider, Marie Follo, PhD, Johannes Waldschmidt, Martina Kleber, Ralph Waesch, MD, Monika Engelhardt, MD

Blood (2013) 122 (21): 3851.

https://doi.org/10.1182/blood.V122.21.3851.3851

Published: 2013

Journal Articles

Individual Patient Data Of Conditional Survival Analysis In a Large Cohort Of 816 Multiple Myeloma (MM) Patients Constitutes a Different Way To Identify Patients With Extended Life Expectancy

Martina Kleber, Stefanie Hieke, Milena Pantic, Bernd Koch, Gabriele Ihorst, Ralph Waesch, MD, Philippe Moreau, MD, Martin Schumacher, Monika Engelhardt, MD

Blood (2013) 122 (21): 1745.

https://doi.org/10.1182/blood.V122.21.1745.1745

Published: 2013

Journal Articles

Conditional Survival Analysis in a Large Cohort of Multiple Myeloma Patients Provides Detailed Information about Long-Term Survival and Constitutes a Different Way to Identify Patients with Extended Life Expectancy

Martina Kleber, Stefanie Hieke, Bernd Koch, Gabriele Ihorst, Ralph Wäsch, Martin Schumacher, Monika Engelhardt

Blood (2012) 120 (21): 4982.

https://doi.org/10.1182/blood.V120.21.4982.4982

Published: 2012

Journal Articles

Bone Marrow Interaction in Multiple Myeloma Pathogenesis: Phenotypical Analysis, Kinetics and Novel Therapy Approaches Based On CXCR4 Inhibition.

Johannes Waldschmidt, Dagmar Wider, Marie Follo, PhD, Josefina Udi, MD, Martina Kleber, Joschka Lorenz, Gabriele Ihorst, Ralph Wäsch, Monika Engelhardt

Blood (2012) 120 (21): 2450.

https://doi.org/10.1182/blood.V120.21.2450.2450

Published: 2012

Journal Articles

Risks for Different Neoplasms (DNs) in Multiple Myeloma (MM) Patients May Involve Specific Host-, Myeloma- and Treatment-Related Susceptibilities: Registry Data of 681 Consecutive MM Patients,

Martina Kleber, Kerstin Höck, Gabriele Ihorst, Bernd Koch, Ralph Waesch, MD, Monika Engelhardt, MD

Blood (2011) 118 (21): 3929.

https://doi.org/10.1182/blood.V118.21.3929.3929

Published: 2011

Journal Articles

Rituximab Plus Bendamustin (R-B) Treatment In Patients with Aggressive Large B-Cell Lymphoma (LBCL): Response and Tolerability - a Single Institution Experience

Julia Horn, Martina Kleber, Ulrike Kohlweyer, Stefanie Hieke, Regina Herzog, Annette Schmitt-Gräff, Monika Engelhardt

Blood (2010) 116 (21): 4900.

https://doi.org/10.1182/blood.V116.21.4900.4900

Published: 2010

Journal Articles

Use of Lenalidomide May Surmount the Adverse Prognosis Induced by Renal Impairment In Patients (pts) with Relapsed/Refractory Multiple Myeloma (MM)

Martina Kleber, Gabriele Ihorst, Josefina Udi, Bernd Koch, Monika Engelhardt

Blood (2010) 116 (21): 3042.

https://doi.org/10.1182/blood.V116.21.3042.3042

Published: 2010

Journal Articles

Initial and Confirmation Analyses of a Detailed Comorbidity and Organ Function Assessment In 593 Multiple Myeloma (MM) Patients (pts) Identify the Freiburger Comorbidity Index (FCI) as a Non-Weighted, Simple, Concise and Cost Effective Comorbidity Score Consisting of 3 Factors Only: Proposal of a Valuable New Tool In MM-Risk Assessment

Meike Terhorst, Martina Kleber, David De Pasquale, Gabriele Ihorst, Monika Engelhardt

Blood (2010) 116 (21): 1901.

https://doi.org/10.1182/blood.V116.21.1901.1901

Published: 2010

Journal Articles

Comparison of 4 Previously Established, but Highly Different Comorbidity Scores (Kaplan Feinstein Index [KF], Charlson-Comorbidity Index [CCI], Satariano Index [SI], Hematopoietic cell transplantation-specific comorbidity index [HCT-CI]) Identifies the KF and HCT-CI as Most Relevant, but Use of An Easily Applied 3-Risk-Factor (KLeber) -Score Suggests to Even More Effectively Predict Progression-Free- and Overall-Survival Differences in Multiple Myeloma (MM) Patients (pts).

Meike Terhorst, Martina Kleber, MD, Gabriele Ihorst, David De Pasquale, Monika Engelhardt

Blood (2009) 114 (22): 1797.

https://doi.org/10.1182/blood.V114.22.1797.1797

Published: 2009

Journal Articles

Sensitive Detection of Renal Function in Multiple Myeloma (MM) Patients (pts) Via Estimated Glomerular Filtration Rate (eGFR) Unmasks Manifest Renal Function in Pts Receiving Lenalidomide and Suggests to Serve as An Additional Predictive Tool of Treatment Response.

Martina Kleber, MD, Peter Haas, Bernd Koch, Manuela Burbeck, Monika Engelhardt

Blood (2009) 114 (22): 4945.

https://doi.org/10.1182/blood.V114.22.4945.4945

Published: 2009

Journal Articles

Detection of Renal Impairment (RI) as One Specific Comorbidity Factor in Multiple Myeloma (MM) Patients: Multi-Center Study in 198 Consecutive Patients

Martina Kleber, Gabriele Ihorst, Barbara Deschler, Christian Jakob, MD, Peter Liebisch, Bernd Koch, Orhan Sezer, Monika Engelhardt

Blood (2008) 112 (11): 2372.

https://doi.org/10.1182/blood.V112.11.2372.2372

Published: 2008

Journal Articles

Analysis of Efficacy, Safety and Costs of Systemic Antifungal Agents in 159 Consecutive High-Risk Cancer Patients for the Establishment of Standardized Guidelines

Werner Neubauer, Martina Kleber, MD, Alf Zerweck, MD, Veronique Thierry, MD, Alexandra Goebel, PhD, Beate Lubrich, PhD, Hartmut Bertz, MD, Monika Engelhardt, MD

Blood (2008) 112 (11): 1313.

https://doi.org/10.1182/blood.V112.11.1313.1313

Published: 2008

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Melphalan Dose in Myeloma Patients over 65 Years of Age Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Importance and Determinants of Comorbidities, Functional Limitations and Multiple Myeloma (MM)-Specific Risk Factors: Further Development of an Improved and Weighted MM-Risk Score (Freiburg Comorbidity Index [FCI])

R-Mini-CHOP Versus R-Bendamustine As Primary Treatment for Diffuse Large B-Cell Lymphoma (DLBCL) in Elderly and Comorbid Patients

Third Autologous Salvage Transplant at Late Myeloma Relapse Is Associated with Favourable Overall Survival and Contributes to Improvement of Exhausted Bone Marrow Function

Vorinostat (V) In Combination With Bortezomib (B), Doxorubicin (D) and Dexamethasone (D) (VBDD) In Patients With Refractory Or Relapsed Multiple Myeloma: An Interim Phase I/II Analysis

Estimation Of GFR With Different EGFR Equations In Multiple Myeloma Patients Receiving Lenalidomide Treatment

Second Malignant Neoplasms Following Multiple Myeloma: A Cohort Study On 744 Patients Treated 1997-2011

Targeting The Protective Microenvironment In Multiple Myeloma (MM): An Analysis Of The CXCL12/CXCR4-Axis and Its Inhibitors AMD3100 and Nox-A12 Combined With Antimyeloma Substances, Such As Pomalidomide and Carfilzomib

Individual Patient Data Of Conditional Survival Analysis In a Large Cohort Of 816 Multiple Myeloma (MM) Patients Constitutes a Different Way To Identify Patients With Extended Life Expectancy

Conditional Survival Analysis in a Large Cohort of Multiple Myeloma Patients Provides Detailed Information about Long-Term Survival and Constitutes a Different Way to Identify Patients with Extended Life Expectancy

Bone Marrow Interaction in Multiple Myeloma Pathogenesis: Phenotypical Analysis, Kinetics and Novel Therapy Approaches Based On CXCR4 Inhibition.

Risks for Different Neoplasms (DNs) in Multiple Myeloma (MM) Patients May Involve Specific Host-, Myeloma- and Treatment-Related Susceptibilities: Registry Data of 681 Consecutive MM Patients,

Rituximab Plus Bendamustin (R-B) Treatment In Patients with Aggressive Large B-Cell Lymphoma (LBCL): Response and Tolerability - a Single Institution Experience

Use of Lenalidomide May Surmount the Adverse Prognosis Induced by Renal Impairment In Patients (pts) with Relapsed/Refractory Multiple Myeloma (MM)

Sensitive Detection of Renal Function in Multiple Myeloma (MM) Patients (pts) Via Estimated Glomerular Filtration Rate (eGFR) Unmasks Manifest Renal Function in Pts Receiving Lenalidomide and Suggests to Serve as An Additional Predictive Tool of Treatment Response.

Detection of Renal Impairment (RI) as One Specific Comorbidity Factor in Multiple Myeloma (MM) Patients: Multi-Center Study in 198 Consecutive Patients

Analysis of Efficacy, Safety and Costs of Systemic Antifungal Agents in 159 Consecutive High-Risk Cancer Patients for the Establishment of Standardized Guidelines

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only